Streetbeat News

Stock Prices

BKNG

Booking Holdings (NASDAQ:BKNG) has significantly outperformed the market over the past 20 years, with an average annual return of 29.79%. A $100 investment in BKNG 20 years ago would be worth $18,428.06 today. This highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 6:00 pm

V

Visa (NYSE:V) has significantly outperformed the market over the past decade, with an annualized return of 18.39%. A $100 investment in Visa 10 years ago would now be worth $547.08, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 6:00 pm

TNDM

Analysts have varied ratings for Tandem Diabetes Care (NASDAQ:TNDM), with a mix of bullish and indifferent sentiments. The average 12-month price target has increased to $50.57. Tandem Diabetes Care has shown revenue growth but faces challenges with negative net margins and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 6:00 pm

DJT

Trump Media & Technology Group Corp. (NASDAQ:DJT) shares are trading lower due to the expiration of a lockup period, allowing large shareholders to sell shares. Despite Trump's decision not to sell his shares, the stock has fallen over 25% and is trading below its 50-day moving average.

Portfolio Pulse from Erica Kollmann

September 23, 2024 | 5:57 pm

RIVN

Rivian Automotive's stock is trading higher due to a proposed U.S. ban on Chinese-made vehicles, which could reduce competition for Rivian. The company also benefits from reduced borrowing costs following a federal interest rate cut. Analysts have mixed ratings on Rivian, with a 12-month price target averaging $17.47.

Portfolio Pulse from Erica Kollmann

September 23, 2024 | 5:52 pm

VSEE

VSee Health's shares are trading higher following the announcement of improved year-over-year Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:47 pm

ASMB

Assembly Biosciences' investigational herpes treatment, ABI-5366, shows promising antiviral efficacy and safety in Phase 1a trials. The drug demonstrated a favorable safety profile and exceeded target plasma concentrations for efficacy. The company is progressing to Phase 1b trials.

Portfolio Pulse from Vandana Singh

September 23, 2024 | 5:39 pm

BHVN

BMY

BNTX

CI

GMED

JNJ

MNKD

PFE

TGTX

VKTX

The article highlights unusual options activity in the health care sector, focusing on large transactions by 'whales' in various stocks. Notable mentions include bullish call sweeps for Pfizer (PFE), BioNTech (BNTX), and MannKind (MNKD), and bearish put sweeps for TG Therapeutics (TGTX) and Globus Medical (GMED).

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 5:35 pm

AMZN

BABA

CVNA

F

FL

LVS

NKE

NWL

SBUX

TSLA

The article highlights unusual options activity in the Consumer Discretionary sector, focusing on large trades by 'whales' in companies like BABA, NWL, TSLA, NKE, CVNA, AMZN, FL, F, SBUX, and LVS. These trades indicate potential bullish or bearish sentiments, which could impact stock prices.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 5:35 pm

AMD

DOCN

HPE

MARA

MSTR

MU

NVDA

PLTR

SMCI

SNOW

The article highlights unusual options activity for several IT stocks, indicating potential trading opportunities. Notable mentions include NVDA, SMCI, MARA, MU, MSTR, SNOW, PLTR, DOCN, AMD, and HPE, with varying sentiments and expiration dates.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 5:35 pm